Colorectal cancer is the third most common cancer and the third leading cause of mortality among men and women. The research saw an estimated 132,700 new cases and an estimated 49,700 deaths from colorectal cancer in 2015, of which 30% to 50% of patients will develop liver metastases.

The treatment of patients with metastatic colorectal cancer is multidisciplinary, involving surgeons, medical oncologists, radiation oncologists, radiology, interventional radiologists and oncologists, gastroenterologists, and ancillary staff. Overall, 5-year survival after resection in patients with colorectal liver metastases varies from 40% to 60% in large series, and 10-year survival is up to 30% in some series. Two large series of more than 2,000 patients reported a 5-year survival of approximately 40%.

R0 resection margins are the goal of surgical resection. A positive margin increases the risk of local recurrence and compromises long-term survival.

Analyses of the American College of Surgeons–National Surgical Quality Improvement Project database have reported a 30-day mortality of 2.5% and a major morbidity rate of 19.6%. A subset analysis of patients with metastatic disease has reported an even lower 30-day mortality (1.3%).

In conclusion, chemotherapy and resection remain the backbone of the treatment of colorectal liver metastases. a multidisciplinary approach is recommended accompanied by best supportive care, and, in cases of disease progression, functional status decline, inability to tolerate treatment, and patient wishes